Edition:
United States

Sumitomo Chemical Co Ltd (4005.T)

4005.T on Tokyo Stock Exchange

608JPY
1:22am EDT
Change (% chg)

¥-6 (-0.98%)
Prev Close
¥614
Open
¥612
Day's High
¥617
Day's Low
¥606
Volume
4,029,000
Avg. Vol
9,086,820
52-wk High
¥682
52-wk Low
¥396

Latest Key Developments (Source: Significant Developments)

Sumitomo Chemical says application of International Financial Reporting Standards
Wednesday, 31 May 2017 02:58am EDT 

May 31 (Reuters) - Sumitomo Chemical Co Ltd <4005.T>:* Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles.* Says IFRS effective from financial statement for fiscal year ending March 2018.  Full Article

Sumitomo Chemical and Sumitomo Metal Mining plan to construct LNG terminal -Nikkei
Tuesday, 30 May 2017 05:59pm EDT 

May 31 (Reuters) - Nikkei -:Sumitomo Chemical and Sumitomo Metal Mining Plan to construct a liquefied natural gas receiving terminal and a gas-fired power plant in Ehime prefecture - Nikkei.Project will cost around 60 billion yen to 70 billion yen ($541 million to $632 million), with work slated to begin in fiscal 2017 - Nikkei.  Full Article

Sumitomo Dainippon Pharma announces application of International Financial Reporting Standards
Monday, 29 May 2017 04:55am EDT 

May 29(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles.IFRS effective from financial statement for fiscal year ending March 2018.  Full Article

Koei Chemical to sell land
Tuesday, 25 Apr 2017 12:32am EDT 

April 25(Reuters) - Koei Chemical Co Ltd <4367.T>:Says it will sell a plot of land in Osaka, to Nitori Holdings Co.,Ltd <<<9843.T>>> ,on June 30.  Full Article

Koei Chemical to sell land in Osaka
Thursday, 26 Jan 2017 11:08pm EST 

Koei Chemical Co Ltd <4367.T> :Says it plans to sell a plant of land located in Osaka at an undisclosed price on March 31.  Full Article

Sumitomo Chemical to buy out its JV with Trinseo - Nikkei
Wednesday, 25 Jan 2017 02:08pm EST 

Nikkei:Sumitomo Chemical to buy out its joint venture with America's Trinseo for tens of millions of dollars - Nikkei.  Full Article

Sumitomo Dainippon Pharma to buy Tolero Pharmaceuticals via unit
Wednesday, 21 Dec 2016 02:45am EST 

Sumitomo Dainippon Pharma Co Ltd <4506.T> :Says co plans to fully acquire 100 percent stake in Tolero Pharmaceuticals, Inc via co's US-based unit, at up to $780 million (advisory fees excluded), in Feb. 2017.  Full Article

Sumitomo Dainippon Pharma plans merger between units
Tuesday, 20 Dec 2016 11:55pm EST 

Sumitomo Dainippon Pharma Co Ltd <4506.T> : Says co's wholly owned unit Boston Biomedical, Inc will merge with co's another US-based unit Boston Biomedical Pharma, Inc, on April 1, 2017 .Says Boston Biomedical Pharma, Inc will be dissolved after the transaction.  Full Article

Sumitomo Chemical and Zeon announce S-SBR business integration and to set up JV
Friday, 2 Dec 2016 01:20am EST 

Sumitomo Chemical <4005.T> and Zeon <4205.T>: Announces integration of S-SBR business . The two company will set up a JV in Tokyo on Dec. 8 . They will transfer their S-SBR business to the JV . The JV will be engaged in purchase, sale, R & D, manufacturing and processing of synthetic rubber .Zeon will hold 60 percent and Sumitomo Chemical will hold 40 percent stake in the JV.  Full Article

Excel Crop Care becomes unit of Japan's Sumitomo Chemical Co Ltd
Friday, 7 Oct 2016 08:31am EDT 

Excel Crop Care: Sumitomo Chemical Co Ltd, Japan now promotoers of co holding 44.98 percent of co's paid up share capital . Shroff Family cease to be promoter of the co with immediate effect . Dipesh Shroff resigned as managing director; Chetan Shah appointed as MD with immediate effect .Co becomes unit of Sumitomo Chemical Co Ltd, Japan.  Full Article

More From Around the Web

BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin

* Says its unit Sumitomo Dainippon Pharma Co Ltd announced today that the company decided to unblind the BRIGHTER study, a phase 3 global study in patients with gastric and gastro-esophageal junction (GEJ) cancer of napabucasin, an investigational cancer stemness inhibitor, based on a recommendation by the study’s independent Data and Safety Monitoring Board (DSMB), following a pre- specified interim analysis